Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 54175446

Drug Profile

JNJ 54175446

Alternative Names: JNJ-54175446; JNJ-5446

Latest Information Update: 25 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen-Cilag
  • Class Antidepressants; Azoles; Phenols; Pyridines; Pyrimidines
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 25 Jul 2022 JNJ 54175446 is still in phase II trials for Major depressive disorder (Adjunctive treatment) in United Kingdom (PO) (NCT04116606) (ISRCTN44411633) (EudraCT2018-001884-21)
  • 05 Nov 2020 Janssen-Cilag reinitiates phase II trial in Major depressive disorder in United Kingdom (ISRCTN44411633) (NCT04116606)
  • 28 Apr 2020 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Belgium (PO, Capsule)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top